The effect of dose on safety, tolerability, and immunogenicity of ACAM2000 smallpox vaccine in adults without previous smallpox vaccination

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Feb 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ACAM 2000 (Primary) ; Smallpox vaccine
Indications Smallpox
Focus Adverse reactions; Pharmacodynamics

Most Recent Events

30 Sep 2008 Primary outcome added as reported by ClinicalTrials.gov.
30 Sep 2008 Study completion date has changed from Mar 2003 to Nov 2003 as reported by ClinicalTrials.gov
30 Sep 2008 Planned number of patients changed from 350 to 353 as reported by ClinicalTrials.gov.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight